As the Clinton administration's health care reform juggernaut finally, officially, fizzled out last week, we were struck by how much it had become a familiar part of the landscape. And the relative quietude clearly demonstrates how noisy the last two years have been since the administration dressed up drug companies as the enemy.

For many in the biotechnology industry, the capital rationing death march that began in January and February of 1993 must seem so normal by now that, like Lebanon, Northern Ireland and other conflicts seemingly without end, any other business environment must be dismissed as folklore or fantasy.

Nevertheless, life does go on. The industry needs to keep an accurate perspective on what was accomplished in the health care debate and own up to the business agenda that remains.

Public policy agenda